GUILFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (NASDAQ: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences tools company commercializing a unique single molecule protein sequencing platform, today announced that it acquired Majelac Technologies LLC, a privately-owned company providing semiconductor packaging and integrated circuit assembly services. The acquisition secures best-in-class semiconductor chip assembly and packaging capabilities for Quantum-Si in order to secure its supply chain and support scaling commercialization efforts.
“The acquisition of Majelac brings chip assembly and packaging capabilities in-house, and it also accelerates our ability to scale up operations to meet demand and support future chip designs,” said John Stark, Chief Executive Officer of Quantum-Si. “This strategic acquisition and vertical integration allow us to secure our supply chain to meet customer demand amidst existing global semiconductor supply chain issues.”
“Since its founding in 2002, Majelac began with a simple goal in mind: to offer a higher caliber of quick-turn integrated circuit assembly services to the semiconductor industry,” said Michael Quinn, Founder and President of Majelac. “We are excited to bring our technical expertise and capabilities to Quantum-Si and support the Company’s goal to digitize and scale proteomics research.”
“We have worked directly with the Majelac team for several years and have always admired their high quality and speed,” said Matt Dyer, Chief Business Officer of Quantum-Si. “We are pleased to welcome the entire Majelac team who are joining Quantum-Si in our mission to transform single molecule analysis and democratize access to the proteome.”
About Quantum-Si
Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward looking statements include, without limitation, the Company’s expectations with respect to future performance and development of products and services; the Company’s other strategic plans for its business; the use of the Company’s technology to expand life sciences markets, the understanding of molecular changes that cause disease, and the development of new biomarkers; and the demand for its products. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on The Nasdaq Stock Market; the ability to recognize the anticipated benefits of the recently completed business combination, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development activities; the potential attributes and benefits of the Company's products and services; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is developing; the size and growth potential of the markets for the Company's future products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services following anticipated commercial launch; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, including those under "Risk Factors" therein, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
